Enveric Biosciences, Inc.

Enveric Biosciences, Inc. reported a net loss of $8.8 million for fiscal year 2025, consistent with its pre-revenue biotech status. The company's operations were funded by raising approximately $10.5 million from sales of common stock and warrants. Total operating expenses were $8.8 million, comprising $5.8 million in general and administrative expenses and $2.8 million in research and development. The company ended the year with $4.7 million in cash and total assets of $5.1 million, while reporting an accumulated deficit of $114.8 million. Management expressed substantial doubt about the company's ability to continue as a going concern, noting current cash is insufficient for the next 12 months of operations.

Key Takeaways